Results 171 to 180 of about 13,289,433 (300)

Comparison of DPP-4 Inhibitors

The Journal of Korean Diabetes, 2013
Nam Hoon Kim, Sin Gon Kim
openaire   +1 more source

Person‐Reported and Continuous Glucose Monitoring (CGM) Recorded Hypoglycaemia in People With Insulin‐Treated Type 2 Diabetes and Mild to Moderate Chronic Kidney Disease; Post Hoc Analysis From the Hypo‐METRICS Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aims People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH) in people with insulin‐treated Type 2 diabetes (T2D) with and without CKD in the Hypo‐METRICS study.
Julie M. B. Brøsen, Daniel Malmsiø, Patrick Divilly, Gilberte Martine‐Edith, Natalie Zaremba, Namam Ali, Rory J. McCrimmon, Simon Heller, Mark Evans, Bastiaan de Galan, Julia K. Mader, Eric Renard, Allan A. Vaag, Pratik Choudhary, Ulrik Pedersen‐Bjergaard, on behalf of the HypoRESOLVE Consortium, Andrew Pernet, Amy Aldridge, Marcia Henderson‐Wilson, Pernille Banck‐Petersen, Rikke Carstensen, Charlotte Hansen, Sharon Caunt, Sue Hudson, Chloe Husband, Fahad Arshad, Anne Farret, Anne‐Marie Marteil‐Oudrer, Manal Shbat, Lisa Crespy, Jenny Constanza Thibout, Anja Rasing, Jesper Walburgh Schimidt, Daniel Loewenstein, Renate Huijsmans, Pieter Drijver, Daniel Chapman, Jane Kennet, Anna Barnett, Jackie Lindsay   +39 more
wiley   +1 more source

Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. [PDF]

J Diabetes Investig
Kubota-Okamoto S, Kubota S, Tsuchida H, Liu Y, Banno S, Imaizumi T, Fujisawa T, Takahashi Y, Kato T, Horikawa Y, Iizuka K, Murakami T, Fujiwara Y, Kuwata H, Yamazaki Y, Seino Y, Tsunekawa S, Yabe D.   +17 more
europepmc   +1 more source

Gingival-Dominant Presentation of DPP-4 Inhibitor-Associated Bullous Pemphigoid: A Case Report. [PDF]

Cureus
Fujii Y, Kataoka T, Togashi C, Ishikawa M, Kawase-Koga Y.   +4 more
europepmc   +1 more source

Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients? [PDF]

North Clin Istanb, 2022
Erol RS, Sen EC, Ozturk FY, Sarac Z, Kokoglu GL, Canat MM, Yildiz D, Aytekin YE, Sevgi DY, Altuntas Y.   +9 more
europepmc   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source

Preclinical pharmacological profiles of cofrogliptin, a novel and bi-weekly DPP-4 inhibitor. [PDF]

Front Pharmacol
Gou X, Dou C, Tang P, Zheng X, Zhang C, Wang J, Meng Q, Wang J.   +7 more
europepmc   +1 more source

Genetic and Clinical Determinants of Variation in Drug Response in Type 2 Diabetes: Insights From the Scottish and UK Biobank Cohorts

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Treatment response in type 2 diabetes (T2D) varies widely among individuals. This study aimed to quantify the contributions of clinical characteristics and genetic predisposition as measured through partitioned polygenic risk scores (pPRS) to variation in glycemic response to glucose‐lowering therapies.
S. Garg, R. Kitchen, R. Gupta, L. Donnelly, E. R. Pearson   +4 more
wiley   +1 more source

Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study. [PDF]

Drug Des Devel Ther
Hung KC, Weng HL, Chen IW.
europepmc   +1 more source

Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes. [PDF]

J Manag Care Spec Pharm, 2021
Kheloussi S, Johns A, Parente V, McLay W, Gionfriddo MR.   +4 more
europepmc   +1 more source